133 related articles for article (PubMed ID: 26709239)
1. Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms.
Kaltenborn A; Matzke S; Kleine M; Krech T; Ramackers W; Vondran FW; Klempnauer J; Bektas H; Schrem H
J Surg Oncol; 2016 Feb; 113(2):194-202. PubMed ID: 26709239
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Talamonti MS; Hall CR; Thurow TA; Gage MK; Stocker SJ; Lapin B; Wang E; Silverstein JC; Mangold K; Odeleye M; Kaul KL; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA
Surgery; 2014 Dec; 156(6):1504-10; discussion 1510-1. PubMed ID: 25456943
[TBL] [Abstract][Full Text] [Related]
6. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
[TBL] [Abstract][Full Text] [Related]
8. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
9. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
12. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
13. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
14. Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis.
Gaitanidis A; Patel D; Nilubol N; Tirosh A; Sadowski S; Kebebew E
Ann Surg Oncol; 2018 Jan; 25(1):122-130. PubMed ID: 29134377
[TBL] [Abstract][Full Text] [Related]
15. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
[TBL] [Abstract][Full Text] [Related]
16. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
[TBL] [Abstract][Full Text] [Related]
18. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
20. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
